PHOENIX, Jan. 27, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model. Using the classical "ischemia/reperfusion" system, collaborators of the Company demonstrated significant reduction in markers of kidney injury at multiple timepoints after kidneys were clamped to replicate renal injury.
"Kidney failure is a significant cause of suffering today. One particular area of kidney damage that is of great interest is preventing injury associated with cardiovascular bypass. One report states that as many as 30% of patients undergoing bypass have some level of renal damage1." Said Dr. Amit Patel, co-inventor of the patent and Board Member of the Company. "The preliminary animal data suggests that ImmCelz® may have superior activity to conventional stem cell based approaches. This may be due to the smaller size of immune cells that comprise the ImmCelz® product, as well as due to factors we are still investigating."
According to a BCC Research Report, entitled "Chronic Kidney Disease: Global Markets and Technologies Through 2023" the global market for chronic kidney disease is anticipated to grow from $79.0 billion in 2018 to reach $95.0 billion by 2023 at a compound annual growth rate (CAGR) of 3.8% for the period of 2018-20232.
"It is important to note that the JadiCell, which has been demonstrated by a double-blind placebo controlled clinical trial to be effective against COVID-19 lung failure3, is the "engine" behind ImmCelz® said Timothy Warbington, President and CEO of the Company. "The demonstration that this cell type, which already has cleared FDA trials, can bestow regenerative properties to blood cells is, in our minds, paradigm shifting. We are excited to include this technology in our robust intellectual property portfolio and eager to file our Investigational New Drug application (IND) with the FDA to begin clinical trials."
The JadiCell clinical trial consisted of 24 patients randomized 1:1 to either JadiCell (UC-MSC) treatment (n = 12) or the control group (n = 12). According to the publication, treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS4.
About Creative Medical Technology Holdings Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.